4//SEC Filing
Avagliano Mark 4
Accession 0001562180-24-000323
CIK 0001560241other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 6:02 AM ET
Size
18.8 KB
Accession
0001562180-24-000323
Insider Transaction Report
Form 4
Avagliano Mark
Chief Business Officer
Transactions
- Sale
Common Stock
2024-01-04$2.94/sh−721$2,121→ 117,834 total - Award
Common Stock
2024-01-03+44,760→ 121,915 total - Sale
Common Stock
2024-01-03$3.12/sh−758$2,364→ 121,157 total - Award
Stock Options (Right to Buy)
2024-01-03+89,400→ 89,400 totalExercise: $2.97Exp: 2034-01-03→ Common Stock (89,400 underlying) - Sale
Common Stock
2024-01-03$3.12/sh−2,602$8,115→ 118,555 total
Footnotes (10)
- [F1]Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2025 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- [F10]The shares underlying this option vest as to 25% of the shares on January 3, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]Each RSU represents a contingent right to receive one share of Issuer common stock.
- [F3]Represents (i) 9,930 shares of common stock; (ii) 4,125 RSUs from award granted on January 4, 2021; (iii) 7,500 RSUs from award granted on January 3, 2022; (iii) 20,600 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 44,760 RSUs from award granted on January 3, 2024.
- [F4]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover' transaction and do not represent discretionary transactions by the Reporting Person.
- [F5]The price represents the weighted average price with a low of $3.08 and a high of $3.16. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]Represents (i) 10,672 shares of common stock; (ii) 4,125 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iii) 20,600 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 44,760 RSUs from award granted on January 3, 2024.
- [F7]Represents (i) 13,220 shares of common stock; (ii) 4,125 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iii) 15,450 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 44,760 RSUs from award granted on January 3, 2024.
- [F8]The price represents the weighted average price with a low of $2.89 and a high of $3.00. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]Represents (i) 13,874 shares of common stock; (ii) 2,750 RSUs from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iii) 15,450 RSUs from award granted on January 3, 2023; (iv) 35,000 RSUs from award granted on May 10, 2023; and (v) 44,760 RSUs from award granted on January 3, 2024.
Issuer
G1 Therapeutics, Inc.
CIK 0001560241
Entity typeother
Related Parties
1- filerCIK 0001783503
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 6:02 AM ET
- Size
- 18.8 KB